Mepolizumab reduces exacerbations and improves asthma control - Video abstract [ID 298559]

(3:1econd)

Mepolizumab for eosinophil associated COPD: METREX and METREO - Video abstract [ID 294333]

(2:58)

Module 5 Treatment Mepolizumab Reslizumab Benralizumab

(15:25)

Mepolizumab depletes inflammatory but preserves homeostatic eosinophils in severe asthma.

(3:32)

Mepolizumab and Omalizumab - Evidence for Use in Severe Asthma -- BAVLS

(9:20)

Could EGPA be Treated with Biologics?

(28:29)

Pharmacology of Mepolizumab (Nucala) ; Mechanism of action, Pharmacokinetics, Uses, Effects

(2:17)

Mepolizumab: Attacking Asthma Associated with Eosinophils

(3:59)

Nucala (Mepolizumab) - Asthma

(2:28)

AAAAI: Mepolizumab Can Replace Steroids in Hypereosinophilic

(6:10)

Michael Wechsler: How Mepolizumab Helps EGPA Patients

(3:7)

IL-5–Inhibiting Agents Mepolizumab, Benralizumab, and Reslizumab

(5:41)

New COPD Clinical Trial: Mepolizumab for Pulmonary Disease, Chronic Obstructive

(1:17)

#mepolizumab | Uses, Dosage, Side Effects and Mechanism | Nucala

(6:51)

Potential impact of mepolizumab in stepping down anti-osteporotic treatment in cortic... | RTCL.TV

(30)

Allergy Journal Club (Heath)

(50:8)

MedX Episode 11: the Latest from World of Medicine

(2:19)

Reducing Exacerbations in COPD

(2:)

Raising Awareness of EGPA: Optimal Diagnostic, Therapeutic, and Team-Based Care Strategies

(37:4)